Pharvaris (PHVS) has released an update.
Pharvaris, a biopharmaceutical company, has showcased promising data at the Bradykinin Symposium 2024 for their oral drug candidate deucrictibant, aimed at preventing and treating hereditary angioedema (HAE). The presented studies demonstrate deucrictibant’s long-term safety and efficacy, including significant reductions in attack occurrence and improvements in patient quality of life. This supports the potential of deucrictibant as a novel oral prophylactic and on-demand therapy for HAE.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
